posted on 2023-06-21, 14:20authored byAki Morikawa, Jinju Li, Peter Ulintz, Xu Cheng, Athena Apfel, Dan Robinson, Alex Hopkins, Chandan Kumar-Sinha, Yi-Mi Wu, Habib Serhan, Kait Verbal, Dafydd Thomas, Daniel F. Hayes, Arul M. Chinnaiyan, Veerabhadran Baladandayuthapani, Jason Heth, Matthew B. Soellner, Sofia D. Merajver, Nathan Merrill
Clinicopathologic characteristics of source patients for brain metastases PDX models: Group B.
Funding
American Society of Clinical Oncology (ASCO)
Breast Cancer Research Foundation (BCRF)
UM | Comprehensive Cancer Center, University of Michigan (U-M Comprehensive Cancer Center)
HHS | National Institutes of Health (NIH)
History
ARTICLE ABSTRACT
Examining genomic alterations and differentially expressed pathways in brain metastases may inform future therapeutic strategies. This study supports genomically-guided therapy for BCBM and further investigation into incorporating real-time functional evaluation will increase confidence in efficacy estimations during drug development and predictive biomarker assessment for BCBM.